These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9378047)
1. [Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease]. Neumann FJ; Gawaz M; Schömig A Dtsch Med Wochenschr; 1997 Oct; 122(40):1224-30. PubMed ID: 9378047 [No Abstract] [Full Text] [Related]
2. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists]. Araujo R; Agustí A Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849 [No Abstract] [Full Text] [Related]
4. In search of a superaspirin for the heart. Verheugt FW Lancet; 1997 May; 349(9063):1409-10. PubMed ID: 9164311 [No Abstract] [Full Text] [Related]
5. Advances in antithrombotic therapy of acute myocardial infarction. Gensini GF; Comeglio M; Falai M Am Heart J; 1999 Aug; 138(2 Pt 2):S171-6. PubMed ID: 10426878 [TBL] [Abstract][Full Text] [Related]
6. Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction. Ferrario M; Repetto A; Lucreziotti S; Ardissino D Am Heart J; 1999 Aug; 138(2 Pt 2):S121-5. PubMed ID: 10426870 [No Abstract] [Full Text] [Related]
7. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
8. Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Subbarao VD; Phillips J; Stouffer GA Am J Med Sci; 1999 Aug; 318(2):107-14. PubMed ID: 10452570 [TBL] [Abstract][Full Text] [Related]
9. What have We learned from ESPRIT? What will we learn from TARGET? Ferguson JJ J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719 [No Abstract] [Full Text] [Related]
10. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519 [TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101 [TBL] [Abstract][Full Text] [Related]
12. [Glycoprotein IIb/IIIa antagonists]. Hennemann A Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193 [No Abstract] [Full Text] [Related]
13. Management of acute coronary syndromes. Schulman SP; Fessler HE Am J Respir Crit Care Med; 2001 Sep; 164(6):917-22. PubMed ID: 11587971 [No Abstract] [Full Text] [Related]
14. Two new antiplatelet drugs for angioplasty and acute coronary syndromes. Med Lett Drugs Ther; 1998 Sep; 40(1035):89-90. PubMed ID: 9760948 [No Abstract] [Full Text] [Related]
15. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors. Dobesh PP; Latham KA Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642 [TBL] [Abstract][Full Text] [Related]
16. The TARGET trial: hit or miss? Moliterno DJ; Topol EJ Eur Heart J; 2002 Jun; 23(11):835-7. PubMed ID: 12042001 [No Abstract] [Full Text] [Related]
17. Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina. Steinhubl SR; Moliterno DJ Heart Vessels; 1997; Suppl 12():148-55. PubMed ID: 9476567 [TBL] [Abstract][Full Text] [Related]